Saving Neurons. Saving Minds.

Annual Report 2013
**Mission**
The mission of the Alzheimer’s Drug Discovery Foundation (ADDF) is to rapidly accelerate the discovery of drugs to prevent, treat and cure Alzheimer’s disease, related dementias and cognitive aging.

**Approach**
Founded in 1998 by co-chairmen Leonard A. and Ronald S. Lauder of the Estée Lauder cosmetics family, the ADDF provides seed funding for early-stage drug research that may otherwise go unfunded. By supporting leading scientists who are conducting the most promising, innovative Alzheimer’s drug research worldwide, we can work towards finding a cure.

The ADDF is a biomedical venture philanthropy. Many of our grants are structured as mission-related investments, providing a return that is reinvested in new drug research.

In 2013, 100 percent of your donations went directly to Alzheimer’s drug research and related programs. All of the ADDF’s administrative and overhead costs were covered by a private foundation.

**Impact**
The ADDF has granted more than $65 million to fund close to 450 Alzheimer’s drug discovery programs and clinical trials in academic centers and biotechnology companies worldwide. In 2013, the ADDF carried an active portfolio of 89 research grants.

**Where We Fund**
The ADDF supports the most promising and diverse research projects in countries around the world, including:

- Austria
- Australia
- Belgium
- Canada
- China
- Finland
- France
- Germany
- Ireland
- Israel
- Italy
- Netherlands
- Spain
- Sweden
- Switzerland
- Taiwan
- United Kingdom
- United States
With drug discovery, there is hope.

Today, an estimated 44 million people worldwide are living with Alzheimer’s, a number that will continue to grow exponentially over the next 20 years. There is so much potential in research projects around the world, but we need to continue to invest in science to unlock that potential and bring forth results.

The Alzheimer’s Drug Discovery Foundation remains committed to funding the most promising research and accelerating drug discovery so that we may help bring effective treatments — and hopefully a cure — to those afflicted by this devastating disease.

In 2013, 100 percent of your donation went directly to Alzheimer’s drug research and related programs. With your help, we can save neurons, minds and, ultimately, lives.

With my deepest thanks,

Leonard A. Lauder
Co-Chairman
Saving Neurons. Saving Minds.

Why do neurons lose connectivity and disintegrate as Alzheimer’s progresses? What can we do to prevent this from happening?

1. **Healthy Brain**
   Neurons form an intricate grid of connections which allow different modules of the brain to communicate with each other leading to complex functions like thought, memory, emotion, and reasoning.

2. **Early-Stage Alzheimer’s**
   As the connections between neurons break down, communication between critical centers of the brain begin to fade; the result is mild dementia.

The ADDF funds the development of “neuroprotective” drugs designed to prevent the loss of connections and protect brain cells from decay and death.

3. **Late-Stage Alzheimer’s**
   In the final stages of Alzheimer’s, so many connections are lost that large parts of the brain become cut off, resulting in complete loss of cognitive function and the inability of patients to care for themselves.
A Letter from Howard Fillit, MD

Thanks to your continued support and generosity in 2013, the Alzheimer’s Drug Discovery Foundation (ADDF) was able to fund many innovative, diverse and promising research projects around the world, increasing our likelihood of finding effective treatments — and a cure — for Alzheimer’s.

We now understand many of the mechanisms that cause Alzheimer’s disease. As the disease progresses, neurons (or nerve cells) lose their connections with one another and eventually die, causing the loss of memory and other essential cognitive functions and resulting in dementia.

Developing drugs that protect neurons from damage and death is critical to finding effective, disease-modifying treatments for Alzheimer’s. The ADDF has funded several key research projects in this area in the hope of “saving neurons and saving minds:"

- **Clinical trials of novel drugs to inhibit the degeneration of neurons**: In 2013, the ADDF supported a phase 1 clinical study of a “neuroprotective” agent by biotechnology company Pharmatrophix. Their drug, LM11A-3, prevented the degeneration of neurons in ADDF-funded preclinical research. The company is now raising funds for a phase 2 study.

- **Clinical trials of novel hormones to stimulate neurogenesis and promote neuroprotection**: The ADDF provided funding to Professor Roberta Brinton of the University of Southern California for her drug allopregnanolone, a hormone derivative which stimulates the development of new brain stem cells and is neuroprotective. ADDF seed funding enabled Dr. Brinton to win an $8M grant from the NIH in 2013 to further her research.

- **Repurposing neuroprotective drugs already approved for treating other conditions**. On page 4, we highlight an exciting clinical trial the ADDF is funding to study whether an existing drug for Parkinson’s disease called rasagiline can slow neurodegeneration in patients with Alzheimer’s.

These clinical trials are a snapshot of the great steps we have made toward translating our basic research knowledge into the development of innovative neuroprotective drugs for Alzheimer’s. There are many more studies like these that need funding.

On behalf of all those suffering with dementia and their loved ones, I personally thank you for your ongoing commitment to the ADDF. With your partnership, we CAN accelerate drug discovery and ultimately conquer Alzheimer’s disease.

Howard Fillit, MD
Founding Executive Director and Chief Science Officer

For more information about the ADDF, please visit [www.AlzDiscovery.org](http://www.AlzDiscovery.org)
Spotlight on Research

Can a drug for Parkinson’s disease help slow the progression of Alzheimer’s?

Dr. Jeffrey Cummings is conducting a new study, designed in collaboration with the Alzheimer’s Drug Discovery Foundation’s team of neuroscientists, to find out whether an FDA-approved treatment for Parkinson’s can help slow the progression of Alzheimer’s. Results may be available in as few as two years.

As part of the Alzheimer’s Drug Discovery Foundation’s (ADDF) Program to Accelerate Clinical Trials (PACT), Jeffrey L. Cummings, MD, ScD, is leading a new clinical trial at the Cleveland Clinic Lou Ruvo Center for Brain Health that is investigating rasagiline, an FDA-approved treatment for Parkinson’s disease, a neurodegenerative disease similar to Alzheimer’s disease in many ways. This exciting repurposing opportunity may provide physicians with new and critical evidence to help inform the treatment and care of their patients.

Research has found that the drug may improve symptoms and could modify the course of disease progression by protecting nerve cells from damage and boosting the function of the mitochondria in the brain. This Phase 2a clinical trial will examine whether Alzheimer’s patients treated with rasagiline experience enhanced brain metabolism, indicating an improvement in brain function, compared to patients treated with a placebo.

Dr. Cummings’ project is just one example of how the ADDF’s PACT program is working to repurpose existing FDA-approved drugs, leveraging standing scientific evidence and research to accelerate the drug development process. The ADDF looks forward to exploring more repurposing opportunities to help Alzheimer’s patients.

From left to right, PET scans showing decreasing metabolism in the brain as Alzheimer’s disease progresses.

Jeffrey L. Cummings, MD, ScD
Cleveland Clinic Lou Ruvo Center
for Brain Health
Las Vegas, NV

Additional Research and Partnership Programs | In 2013, ADDF led major research program collaborations of Sciences, The Foundation for Mitochondria Medicine, The Robert A. and Renée E. Belfer Family Foundation
Highlights from the Laboratories

The Alzheimer’s Drug Discovery Foundation (ADDF) is proud to support the innovative research of scientists around the world as they work tirelessly to discover and develop new treatments for Alzheimer’s and related dementias. The following ADDF-funded investigators are leading promising research in neuroprotection, one of many diverse areas that ADDF funds.

Dr. Eugenia Trushina, PhD
Mayo Clinic Rochester
Rochester, MN

Through the ADDF ACCESS program (featured on page 8), Dr. Trushina is working with a contract research organization to develop and test new drug candidates that improve the function of mitochondria, the energy generators of cells. These drug candidates could ultimately improve neuron function and prevent deterioration.

Els Fieremans, PhD
New York University School of Medicine
New York, NY

Dr. Fieremans and her team are investigating whether changes in white matter, one of two types of tissue that make up the brain, can be used as a biomarker to detect early brain changes in people with Alzheimer’s. By identifying and treating patients that will develop Alzheimer’s prior to the onset of symptoms, we can increase the likelihood that treatments will be effective.

Yukari Perrella
Yuma Therapeutics
Cambridge, MA

Yuma Therapeutics is developing novel inhibitors for Hsp90, a protein that regulates the accumulation of the tau protein in the brain — a hallmark of Alzheimer’s disease. Drug candidates developed by this project could potentially protect neurons from dysfunction and prevent tau build up.

The support and funding Yuma Therapeutics has received from ADDF has been transformative, enabling us to advance our program from medicinal chemistry to in vivo proof-of-concept studies.

— Yukari Perrella

with other foundations, including The Association for Frontotemporal Dementia, The New York Academy and other valued partners, leveraging interdisciplinary expertise and funding towards our common goals.

For more information about the ADDF, please visit www.AlzDiscovery.org
Our Patrons Celebrate Hope

A Banner Year for Alzheimer’s Drug Discovery!

Thanks to you, we raised more than $10 million in 2013! Your contributions helped fund critical Alzheimer’s drug research and related programs, and provided hope to those burdened by Alzheimer’s disease.

For the first time, more than 2,000 people came together to support the Alzheimer’s Drug Discovery Foundation (ADDF) and our mission. Every single one of your contributions helped advance critical Alzheimer’s research — imagine what we can achieve together in the future!

Thank you for making 2013 a banner year for the ADDF!

Nancy M. Sanford  
Vice President and Chief Philanthropy Officer

In an effort to broaden awareness and raise critical funds for Alzheimer’s research, the Alzheimer’s Drug Discovery Foundation (ADDF) hosted several major special events in 2013.

Third Annual Great Ladies Luncheon and Fashion Show
Saks Fifth Avenue  |  Chevy Chase, MD  |  April 11, 2013

Co-Chairs  |  Leonard A. Lauder  |  Elise and Marc Lefkowitz

In partnership with Saks Fifth Avenue, the ADDF’s third annual Great Ladies Luncheon and Fashion Show raised nearly $270,000. Guests enjoyed a runway show and special appearance by famed designer Jason Wu, and Sharon Percy Rockefeller received the Great Ladies Award.

Above: Jason Wu model on runway. Jason Wu, Elise Lefkowitz and Marc Lefkowitz.
Seventh Annual Connoisseur’s Dinner: To Live is to Think
Sotheby’s | New York, NY | May 2, 2013

Event Chairs | Leonard A. Lauder | Nancy Corzine

The ADDF’s seventh annual Connoisseur’s Dinner raised $1.7 million for scientific drug research for Alzheimer’s. Paula Zahn was awarded the third annual Chairman’s Award, and Sotheby’s Chairman Jamie Niven conducted the “Fund a Scientist” live auction, raising a record $475,000 onsite for a single scientist’s research.


Fourth Annual Fall Luncheon & Symposium
Hope on the Horizon: New Drugs for Alzheimer’s Disease
The Pierre | New York, NY | September 17, 2013

Executive Chair | Leonard A. Lauder

The ADDF’s fourth annual Fall Luncheon and Symposium raised more than $795,000 for Alzheimer’s drug research and related programs. Bonnie Pfeiffer Evans and Alice Shure presented The Charles Evans Award to Liz and Randal Sandler, who announced a $1 million matching challenge grant, calling on other supporters to make a pledge — at any level — to support clinical trials. Paula Zahn moderated an insightful conversation between Howard Fillit, MD, and Jeffrey L. Cummings, MD, ScD, director of the Cleveland Clinic’s Lou Ruvo Center for Brain Health.


For more information about the ADDF, please visit www.AlzDiscovery.org
Bringing Scientists Together To Accelerate Alzheimer's Research

The Alzheimer's Drug Discovery Foundation's (ADDF) scientific conferences and resource programs promote the exchange of ideas, the sharing of research results and the formation of strategic alliances to further drug development goals.

7th Drug Discovery for Neurodegeneration Conference: An Intensive Course on Translating Research into Drugs
San Francisco, CA
February 10-12, 2013
The ADDF’s annual conference, planned in conjunction with the National Institutes of Health, attracted approximately 140 academic, industry and government scientists from around the world. Designed to advance the development of new drugs for neurodegenerative diseases, the conference educated scientists on the principles and practice of drug discovery with a focus on Alzheimer’s disease, Parkinson’s disease, Amyotrophic Lateral Sclerosis and Multiple Sclerosis.

14th International Conference on Alzheimer’s Drug Discovery
Jersey City, NJ
September 8-10, 2013
One hundred and forty key stakeholders from the pharmaceutical, biotechnology, government and academic communities came together at this annual conference to present ADDF-funded research and establish collaborations and partnerships to accelerate the development of innovative treatments.

The ADDF also hosted or exhibited at several additional conferences in collaboration with other scientific institutions.

ADDF ACCESS
Helping Scientists Find the Expertise They Need
ADDF ACCESS provides academic and small biotechnology researchers with access to a virtual network of contract research organizations (CROs), drug development experts and educational resources. In 2013, the ADDF expanded and redesigned the platform to make this resource available to the broader scientific community to promote collaboration between scientists investigating different neurodegenerative diseases. This expanded platform was made possible with the support and partnership of The Beyond Batten Disease Foundation, The BrightFocus Foundation and The Children’s Tumor Foundation.

http://www.alzdiscovery.org/research-and-grants/addf-access/

ADDF Aging & Alzheimer’s Prevention Program
Empowering People to Protect Their Aging Brains
ADDF’s Aging and Alzheimer’s Prevention program provides an independent scientific evaluation of the evidence surrounding pharmaceuticals, supplements and natural products that claim to prevent or delay cognitive aging and Alzheimer’s. Because prevention is very difficult to prove scientifically, the program works to enhance innovative approaches to strengthen the evidence for prevention through targeted funding. In 2013, the ADDF funded a grant for computer software that predicts the effectiveness of therapies and organized an advisory panel on using existing data from human studies to guide Alzheimer’s prevention. The ADDF also began development of a new website, Cognitive Vitality, to empower individuals to make choices for their own long-term brain health based on the best available science.

http://www.alzdiscovery.org/cognitive-vitality
Funding Research Around the World

In 2013, we granted more than $8 million to 39 scientists globally.

**Preclinical Drug Discovery Program — Academic**

**Carmela R. Abraham, PhD**
Boston University School of Medicine, Boston, MA
Development of Klotho Enhancers as Novel Therapeutics for AD
*Award: $266,509*

**Narayan Bhat, PhD**
Medical University of South Carolina, Charleston, SC
Vasculoprotective approach to AD treatment
*Award: $230,961*

*The Charles Evans Foundation Award for Excellence in Alzheimer’s Drug Discovery*

**Deborah Blacker, MD**
Massachusetts General Hospital, Charlestown, MA
Alzheimer’s Disease Modifiable Risk Database
*Award: $25,000*

*Aging and Alzheimer’s Disease Prevention Program*

**Els Fieremans, PhD**
New York University School of Medicine, New York, NY
White matter involvement in preclinical AD: a multimodal MR-PET study
*Award: $200,184*

**Massimo Filippi, MD**
Fondazione Central San Raffaele, Milan, Italy
Brain network analysis for the early diagnosis of AD from other dementias
*Award: $125,000*

**Thota Ganesh, PhD**
Emory University, Atlanta, GA
EP2 antagonists for the suppression of inflammation and neuropathology in Alzheimer’s model
*Award: $101,000*

**Xiong Jiang, PhD**
Georgetown University, Washington, DC
A novel fMRI biomarker of asymptomatic Alzheimer’s disease
*Award: $140,000*

**Tae-Wan Kim, PhD**
Columbia University Medical Center, New York, NY
Screening for small molecule modulators of tau in stem cell-derived primary neurons
*Award: $150,000*

**David Knopman, MD**
National Biomedical Research Ethics Council, INC Rockville, MD
National Institutional Review Board for Neurodegenerative Diseases
*Award: $100,000*

**Peter Lansbury, PhD**
Brigham and Women’s Hospital, Boston, MA
Characterizing the mitophenotypes of Alzheimer’s disease: peripheral cell biomarkers for patient selection and measurement of drug response.
*Award: $100,000*

*Alzheimer’s Drug Discovery Foundation/Ronald D. Eastman Fund Award to Accelerate Drug Discovery*

**Ling Li, DVM, PhD**
University of Minnesota, Minneapolis, MN
ApoJ/Clusterin Peptide as a Novel Therapeutic Agent for Alzheimer’s Disease
*Award: $200,000*

**Pei-Jung Lin, PhD**
Tufts University, Boston, MA
Unintended Benefits? The Potential Economic Impact of Chronic Disease Management on Alzheimer’s Prevention
*Award: $25,000*

*Made possible in partnership with funding from the Alzheimer’s Foundation of America*
Chien-liang Lin, PhD
Ohio State University, Columbus, OH
Development of small molecule activators of glutamate transporter EAAT2 translation for Alzheimer’s disease
AWARD: $220,000
Alzheimer’s Drug Discovery Foundation/Alzheimer’s Foundation of America Award to Accelerate Drug Discovery

Salvatore Oddo, PhD
Banner Sun Health Research Institute, Sun City, AZ
Reducing mTOR activity as a treatment for Alzheimer’s disease
AWARD: $242,000

Nathalie Pochet, PhD
Brigham & Women’s Hospital, Boston, MA
Integrative genomic approach to prioritize targets for drug discovery and development in Alzheimer’s disease and aging-related cognitive decline
AWARD: $135,000
Alzheimer’s Drug Discovery Foundation/McCaffrey Fund Award to Accelerate Drug Discovery

Jerri Rook, PhD
Vanderbilt Center of Neuroscience Drug Discovery, Nashville, TN
In Vivo Characterization of Novel mGlu5 PAMs in Aged Rats
AWARD: $150,000

Grace Stutzmann, PhD
Rosalind Franklin University of Medicine and Science, North Chicago, IL
Stabilizing ryanodine calcium channels as a novel drug development strategy for Alzheimer’s disease therapeutics
AWARD: $170,106

Malu Tansey, PhD
Emory University School of Medicine, Atlanta, GA
Modulation of peripheral immunization and immune cell traffic in AD by XPro1595
AWARD: $100,000

Eugenia Trushina, PhD
Mayo Clinic Rochester, Rochester, MN
Lead Discovery of Novel Small Compounds Effective in Restoration of Mitochondrial Function - Year 2
AWARD: $140,000
Supported in part by Sir Evelyn and Lady Lynn Forester de Rothschild

Xiang (Simon) Wang, PhD
Howard University College of Pharmacy, Washington, DC
Highly Selective HDAC2 Inhibitors to Treat Alzheimer’s Disease
AWARD: $110,000
Alzheimer’s Drug Discovery Foundation/Alzheimer’s Foundation of America Award to Accelerate Drug Discovery

Keqiang Ye, PhD
Emory University, Atlanta, GA
TrkB Agonist Drug Development for Treating Alzheimer’s Disease
AWARD: $200,000

Sun Ok Yoon, PhD
Ohio State University, Columbus, OH
Testing novel JNK3-selective inhibitors in Alzheimer’s disease mouse models
AWARD: $158,336

Biotechnology Program — Preclinical

Larry Altstiel, MD, PhD*
Provectra Therapeutics Inc., Chapel Hill, NC
Adeno-Associated Virus Gene Therapy of Progranulin-Related Frontotemporal Dementia
AWARD: $164,750

Dirk Beher, PhD*
Asceneuron SA, Lausanne, Switzerland
O-GlcNAcase Inhibitors for Alzheimer’s disease and Tauopathies
AWARD: $325,000

Martin Jefson, PhD
Rodin Therapeutics, Cambridge, MA
Selective HDAC2 Inhibitors for the Treatment of Cognitive Deficits in Alzheimer’s Disease
AWARD: $182,500

Yukari Perrella
Yuma Therapeutics Corporation, Brookline, MA
The effect of novel heat shock protein 90 (Hsp90) inhibitors on total and phosphorylated tau levels in cerebrospinal fluid and memory deficits in the hTAU441 (tauopathy) mouse transgenic model of Alzheimer’s disease
AWARD: $174,967

Paolo Pevarello, PhD
Axxam SpA, Milan, Italy
Optimization of P2X7 antagonists for AD treatment
AWARD: $310,000

Conference Grants

Enrique Cadenas, MD, PhD
Gordon Research Conferences, West Kingston, RI
Gordon Research Conference on Oxidative Stress and Disease: The metabolic-inflammatory axis in brain aging and Alzheimer’s disease
AWARD: $5,000

Kate Carr
Safe Kids Worldwide, Washington, DC
Safe Sports Think Tank: Exploring the relationship between childhood sports-related concussions and long-term cognitive outcomes
AWARD: $5,000
Program to Accelerate Clinical Trials (PACT)

Jeffrey Cummings, MD
Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV
Rasagiline Rescue in Alzheimer’s Disease Clinical Trial (R2 Trial)
AWARD: $1,000,000

Program to Accelerate Clinical Trials - Repurposing

Anne Longo
PharmatrophiX, Menlo Park, CA
Phase 1 Study for P75 Small Molecule Ligand
AWARD: $250,000

Michelle Mielke, PhD
Mayo Clinic Rochester, Rochester, MN
Evaluation of changes in plasma ceramides and amino compounds with an mTOT Modulator Insulin Sensitizer in AD patients
AWARD: $6,960

ADDF-Belfer ApoE Therapeutics Innovation Program

Bradley Hyman, MD, PhD
Massachusetts General Hospital/Harvard Medical School, Charlestown, MA
APOE2-based gene therapy approaches to alleviate Alzheimer’s disease neuropathological hallmarks
AWARD: $250,000

Steven Paul, MD
Weill Medical College of Cornell University, New York, NY
Gene Delivery of Apolipoprotein E2 as a Treatment for Alzheimer’s Disease
AWARD: $500,000

ADDF-Association for Frontotemporal Degeneration Partnership Program

Donald Lo, PhD
Duke University Medical Center, Durham, NC
Brain slice screen for microRNA-targeted drug lead candidates for tau-associated FTD
AWARD: $149,603

Jeffrey Rothstein, MD, PhD
Johns Hopkins University School of Medicine, Baltimore, MD
Biomarker assay development to accompany antisense oligonucleotide therapeutic for mutant C9orf72-positive FTD patients
AWARD: $150,168

ADDF-Foundation for Mitochondrial Medicine Partnership Program

James Bennett, MD, PhD
Virginia Commonwealth University, Richmond, VA
Increasing Mitochondrial Biogenesis in Alzheimer’s Disease
Award: $200,000

ADDF-New York Academy of Sciences Partnership Program

Blaine Roberts, PhD
Howard Florey Institute, Victoria, Australia
Validation of an effective blood test for Alzheimer’s disease.
AWARD: $140,000

ADDF-Canada

Sandra Black, MD, FRCP(C)
Sunnybrook Research Institute, University of Toronto, Toronto, Ontario, Canada
Sartans to Slow Alzheimer’s Disease: A Randomized, Open-Label, Head-to-Head, Proof-of-Concept Study of Angiotensin Receptor Blockers Versus ACE Inhibitors
AWARD: $992,388
Made possible through a generous grant by The W. Garfield Weston Foundation to ADDF-Canada

*Grant is in contract.
2013 Scientific Review Board

Every grant application submitted to the Alzheimer's Drug Discovery Foundation is reviewed by a diverse panel of scientists with expertise in a wide-range of Alzheimer's research areas. Thanks to this group for their invaluable contribution in 2013 to Alzheimer's science and drug discovery.

Larry D. Alstiel, MD, PhD
CEO
Provectra Therapeutics Inc.

Pankaj Agarwal, PhD
Director, Systematic Drug Repositioning, Computational Biology
GlaxoSmithKline

Ottavio Arancio, MD, PhD
Associate Professor
Columbia University College of Physicians and Surgeons

Kelly Bales, PhD
Research Fellow, Neuroscience Research Unit
Pfizer

Guriq Basi, PhD
CEO
GSBio LLC

Adam Boxer, MD, PhD
Associate Professor
University of California San Francisco Memory and Aging Center

Jennifer Bizon, PhD
Associate Professor
University of Florida College of Medicine

Roberta Brinton, PhD
Chair in Therapeutic Discovery and Development
University of Southern California

Tilmann Brotz, PhD
Principal Consultant
Konzept Drug Development Consulting

Kurt Brunden, PhD
Director, CNDR Drug Discovery School of Pennsylvania Medicine

Samantha Budd, PhD
Vice President, Neuroscience iMed AstraZeneca R&D

John Cirrito, PhD
Associate Professor
Washington University in St. Louis

Mark Cochran, PhD
Managing Director
Johns Hopkins Healthcare

Greg Cole, PhD
Professor
University of California Los Angeles School of Medicine

Carol Colton, PhD
Professor
Duke University Medical Center

Brad Dickerson, MD
Associate Professor
Harvard Medical School

Joel Dudley, PhD
Director, Biomedical Informatics
Mount Sinai School of Medicine

Stephen Friend, MD, PhD
President & Co-Founder
Sage Bionetworks

Douglas Galasko, MD
Professor
University of California San Diego

Hugo Geerts, PhD
Scientific Liaison Officer
In Silico Biosciences, Inc.

Marcie Glicksman, PhD
Assistant Professor
Harvard Medical School

Paul Gilligan, PhD
Research Scientist
Pennsylvania Drug Discovery Institute

Todd E. Golde, MD, PhD
Director, Center for Translational Research in Neurodegenerative Disease
University of Florida College of Medicine

Allan Green, MD, PhD, JD
Attorney at Law
Allan M. Green Esq., LLC

Barry Greenberg, PhD
Director of Strategy
Toronto Dementia Research Alliance

Jim Hendrix, PhD
Director, Global Science Initiatives
Alzheimer's Association

David Holtzman, MD
Professor and Chairman, Department of Neurology
Washington University in Saint Louis School of Medicine

Keith Hyland, PhD
Vice President
Medical Neurogenetics, LLC

Graham Jones, PhD
Professor and Chairman, Chemistry and Chemical Biology
Northeastern University

Carl Johnson, PhD
Executive Director for Science
Hereditary Disease Foundation

Tae-Wan Kim, PhD
Associate Professor
Columbia University Medical Center

David Knopman, MD
Professor
Mayo Clinic Rochester

Sam Kongsamut, PhD
Executive Director
Neurotrope Bioscience

Jeff Kuret, PhD
Professor
Ohio State University College of Medicine

John Lincecum, PhD
Director, Discovery Biology
ALS Therapy Development
Dane Liston, PhD
Pharmacologist
National Cancer Institute

Elias Michaelis, MD, PhD
Professor
University of Kansas School of Pharmacy

Tetsuyuki Maruyama, PhD
General Manager, Pharmaceutical Research Division
Takeda Cambridge Limited

Richard Mohs, PhD
Vice President, Neuroscience and Clinical Development
Eli Lilly and Company

Bruce Molino, PhD
Senior Director, Medicinal Chemistry
Albany Molecular Research Inc. (AMRI)

Dave Morgan, PhD
Professor
University of South Florida

Jill Murrell, PhD
Associate Professor
Indiana University School of Medicine

Ian Newington, PhD
Principal Scientist
GE Healthcare

Salvatore Oddo, PhD
Senior Scientist
Banner Sun Health Research Institute

Gary Olson, PhD
Co-Founder, President & CEO
Provid Pharmaceuticals Inc.

Gilbert Rishton, PhD
Chief Medicinal Chemistry Advisor
Cognition Therapeutics, Inc.

Gerard Rosse, PhD
Associate Director, Chemistry
Dart Neuroscience

Jack Rogers, PhD
Director, Neurochemistry Laboratory
Massachusetts General Hospital

Thomas Rooney, PhD
Head of Translational Research
Sanofi

Israel Silman, PhD
Professor
The Weizmann Institute of Science

Kumar Sambamurti, PhD
Professor
Medical University of South Carolina

Joel Schachter, PhD
Franchise Collaboration Lead, Neuroscience External Discovery and Preclinical Sciences
Merck

John Shoffner, MD
President & CEO
Medical Neurogenetics, LLC

Einar Sigurdsson, PhD
Associate Professor
New York University School of Medicine

Edward Spack, PhD
Managing Director
Fast Forward LLC

Greg Thatcher, PhD
Professor
University of Illinois at Chicago College of Pharmacy

Martin Tolar, PhD
Founder, President & CEO
Alzheon, Inc.

Linda Van Eldik, PhD
Director, Sanders-Brown Center on Aging
University of Kentucky

Daniel Watterson, PhD
Professor
Northwestern University Feinberg School of Medicine

Michael Weiner, MD
Professor
University of California San Francisco School of Medicine

Manfred Windisch, PhD
President & CEO
NeuroScios GmbH

Michael Wolfe, PhD
Professor
Brigham and Women’s Hospital

Wai Haung Yu, PhD
Assistant Professor
Columbia University Medical Center

---

2013 Business Review Board

Biotechnology grant applications submitted to the Alzheimer’s Drug Discovery Foundation are additionally reviewed by a varied panel of industry experts with backgrounds in venture capital, biotechnology and pharmaceuticals. Thanks to this group for their invaluable contribution in 2013.

Tom Cirrito, PhD
CEO and Founder
Filament BioSolutions, Inc.

Julie Eskay-Eagle, MBA
VP Strategy & Business Development
Real Endpoints LLC

Stephen Goodman, JD
Partner
Pryor Cashman LLP

Emer Leahy, PhD
President & CEO
PsychoGenics

Dan O’Connell, MBA
Managing Partner
NeuroVentures Capital, LLC

Michael Parker, MBA
Managing Partner
BioAsset Advisors

Rana Quraishi, PhD
Director of New Ventures
University of Maryland
Robert H. Smith School of Business

Eric Snyder, PhD
Director
Navigant
Support Alzheimer’s Research

Join us to save neurons and save minds from Alzheimer’s.

There are currently no drugs available to prevent or even slow the course of Alzheimer's, but scientists are making real progress toward a cure. There is hope in drug discovery. With your support, we can and will understand, prevent and conquer this disease.

We are tremendously grateful to all who contributed to the Alzheimer’s Drug Discovery Foundation (ADDF) in 2013.

Over $1,000,000
Mr. and Mrs. Melvin R. Goodes
Mr. Eli S. Jacobs
Mr. and Mrs. Randal B. Sandler

$100,000 to $999,999
Anonymous (5)
Alzheimer’s Foundation of America
The Association for Frontotemporal Degeneration
The Robert A. and Renée E. Belfer Family Foundation
The Estée Lauder Companies Inc.
Foundation for Mitochondrial Medicine
Leslie and Roslyn Goldstein Foundation
The Kaneff Foundation
The Lauder Foundation
Mr. Leonard A. Lauder
Mr. and Mrs. Marc Lefkowitz
Nathan E. Saint-Amand, M.D.
Sotheby’s
The W. Garfield Weston Foundation

$50,000 to $99,999
A.P. Kirby, Jr. Foundation, Inc.
Mr. and Mrs. Ronald A. Altman
Mr. and Mrs. Louis Caceres
Ms. Nancy Corzine
Sir Evelyn and Lady Lynn Forester de Rothschild
Evelyn H. Lauder Charitable Trust
Mrs. Judy Glickman
Mr. and Mrs. Jim Gordon
Insurance Industry Charitable Foundation, Inc.
Mr. and Mrs. Ronald S. Lauder
Mr. Dan Lufkin, The Peter Jay Sharp Foundation
Ms. Carlyn McCaffrey
National Institutes of Health
New York Academy of Sciences
The Polis-Schutz Family Foundation
Mr. and Mrs. Burton Rose
Mr. and Mrs. William F. Ruprecht, Sotheby’s
Mr. and Mrs. Peter J. Solomon
Ms. Julie Weindling and Mr. Philip H. Geier

$25,000 to $49,999
Ms. Carol Seabrook Boulanger
C2N Diagnostics
The Charles Evans Foundation,
Mrs. Bonnie Pfeifer Evans, Co-Trustee
and Mrs. Alice Shure, Co-Trustee
Condé Nast Publications
Mr. and Mrs. Mitchell D. Eichen
Ernst & Young, LLP
First Republic Bank
Flexjet
Mrs. Bonnie Englebardt Lautenberg
Mr. and Mrs. Eric Lefkofsky
Mr. Philip Lovett
Merck Research Laboratories
Mr. and Mrs. Andrew Moller
Mr. and Mrs. Marc S. Moller
National Multiple Sclerosis Society
The Ralph and Ricky Lauren Family Foundation, Inc.
Ms. Lois Robbins and Mr. Andrew Zaro
Emily C. Rose, M.D.
Mr. and Mrs. Gordon Segal
Mr. and Mrs. Steve Shapiro
Staples Advantage
Mrs. Joan Sutton Straus
Teamount and Grace Fulte Foundation
Tishman Speyer Properties, LP
USAgainstAlzheimer’s
Mr. and Mrs. Michael Weisman
Ms. Paula Zahn

$10,000 to $24,999
Abbott Laboratories
Ms. Kellie Abreu
Alzheimer’s Association
Mr. and Mrs. Claude Amadeo
Mr. and Mrs. Gilchrest Berg
Carol Lavin Bernick Family Foundation
Mr. and Mrs. Daniel S. Bernstein
Beyond Batten Disease Foundation
Mr. and Mrs. William Blake
Bloomberg LP
Mr. and Mrs. D. Dixon Boardman, The Optima Charitable Foundation
BrightFocus Foundation
Mr. and Mrs. Daniel Brodsky
Mr. Louis C. Camilleri
Mr. and Mrs. Arthur Carter
Ms. Anne Cox Chambers
Mr. David Deckelbaum
Mr. John D. Demsey
Mr. and Mrs. Warren Diamond
Mr. and Mrs. Joel S. Ehrenkranz
Mr. and Mrs. Robin L. Farkas
Ms. Mary C. Farrell
The Fribourg Family
Mr. and Mrs. Thomas L. Friedman
Mr. and Mrs. Richard I. Furman
Goldman Sachs & Co. Matching Gifts Program
Mr. David Goodes
Ms. Katie Hall and Mr. Tom Knutsen
Ms. Dina Merrill Hartley and Mr. Ted Hartley
INOAC Packaging Group, Inc.
Mr. and Mrs. Robert A. Irvin
Ms. Rose Marie Bravo and Mr. William Jackey
Mr. Gregory Jones
Mr. and Mrs. Howard Kessler
Mr. and Mrs. Gary Lauder
Mr. and Mrs. Jorge F. Lazo
Mr. and Mrs. Laurence C. Leeds, Jr.
Mr. and Mrs. Gerald Levine
Lilly USA, LLC
Mr. and Mrs. Daniel S. Loeb
Ms. Michelle MacDonald
The Honorable and Mrs. Earle I. Mack
Macy’s and Bloomingdale’s
Mr. William E. Mayer
Ms. Judy McLaren
Ms. Anne Welsh McNulty
Michael J. Fox Foundation for Parkinson’s Research
Mr. and Mrs. Lucian Morrison III
Omega Capital Enterprises, LLC
Open Hearts Foundation
Pfizer Inc.
Mr. Thomas Pheasant
Mr. and Mrs. Robert Prince
Mr. and Mrs. John R. Reinsberg
Mr. and Mrs. Daniel Roitman
Mr. and Mrs. William C. Rudin
Mr. and Mrs. Richard E. Salomon
Mr. and Mrs. Nathan Sandler
Mr. and Mrs. George W. Schiele
Mr. and Mrs. Paul C. Schorr III
Mr. and Mrs. Warren L. Schwerin
Mr. Larry Silverstein
Mr. David Solomon
The Sun-Times Foundation
Ms. Mary Rose Taylor
Laurie M. Tisch Illumination Fund
Trish and George Vradenburg, USAgainstAlzheimer’s
Ms. Giselle F. Wagner and Mr. Paul A. Myerson
Dr. and Mrs. Allan Weinstein
Mr. and Mrs. Buzz Zaino
Mr. and Mrs. Robert B. Zink

$5,000 to $9,999
Anonymous
Mr. and Mrs. Carl Allen
Mr. and Mrs. Robert Banks
Mr. and Mrs. Philip J. Bazelides
Ms. Glennis C. Beacham
Ms. Karen H. Bechtel
Bender Foundation, Inc.
Mr. and Mrs. Ted Berghorst, The Berghorst Foundation Inc.
Mr. Ryan Bernardini
Mr. and Mrs. Scott Black
Mr. and Mrs. Roy Bostock
Ms. Mary Ellen Brophy
Ms. Bobbi Brown and Mr. Steven Plofker
Ms. Lynda Carter
Ms. Maureen Case and Mr. Victor Fuentes
Ms. Antoinette Delrue
Mr. and Mrs. Charles M. Diker
Mrs. Cherrie Doggett
Ms. Laurie Dowley and Ms. Thia Breen
Mr. and Mrs. Howard Draft
Mr. and Mrs. Todd Eagle
Father’s Day/Mother’s Day Council, Inc.
Mr. and Mrs. Naille M. Ferguson
Forest Laboratories, Inc.
Ms. Marcia French
Mr. John Galantic, Chanel, Inc.
Mr. Bruce Gelb
Ms. Carol Lanier Goodman
Mr. and Mrs. Mark W. Hennessy
Mr. and Mrs. Roger Hertog
Ms. Marlene Hess and Mr. James D. Zirin
The Howard Johnson Foundation
Mr. and Mrs. James C. Kennedy
Mr. and Mrs. Michael J. Kennedy
Mr. and Mrs. H. Fred Krimendahl II
Ms. Melissa Landais, JPMorgan Chase
Ms. Carol Launer
Mr. and Mrs. Steven Levy
Mrs. Holly Madigan
The Marc Haas Foundation, Mr. and Mrs. Stanley Shuman

For more information about the ADDF, please visit www.AlzDiscovery.org
Mr. and Mrs. Bennett Marshall
Private Banking & Investment Group
at Merrill Lynch
Mr. and Mrs. William Miller
Mrs. Nancy Montgomery
Ms. Pamela J. Newman
Mr. Keith Nickels
Ms. Vivian Niewow and
Ms. Dorothy Loecher
Mr. and Mrs. Larry Nussdorf
Mr. and Mrs. Alan J. Patricof
Mr. and Mrs. Michael Pierce
Printpack Inc. & The Gay and Erskine
Love Foundation
Ms. Joan Rall
Mr. and Mrs. William Rayner
Ms. Margaret Rice
Ms. Denise Rich
Ms. Pilar Crespi Robert and
Mr. Stephen Robert
Mr. and Mrs. Elihu Rose
Ms. Lita Rosenberg
Mr. and Mrs. Jack Rudin
Ms. Patricia Bennett Sagon
Saks Fifth Avenue
William and Jacqueline Shaw
Family Foundation, Inc.
Ms. Lisa B. Spikell
Mr. and Mrs. Cary Stamp
The Honorable and
Mrs. Craig R. Stapleton
Mr. and Mrs. Donald Tober
Mrs. Jeanette Sarkisian Wagner and
Dr. Paul A. Wagner
Mr. and Mrs. John F. Walsh
Walter Family Foundation
Ms. Catherine J. Webb
Ms. Virginia A. Weil
Mr. and Mrs. Ronald Weintraub
Ms. Wendy L. Wilshin
Ms. Linda Zambelli

In Memory

We remember those taken by Alzheimer's in 2013
by continuing to fight for a cure.

Ruth Bachrach
Naomi Banks
Alvin Bernstein
Matthew Bucksbaum
Michael Cauvoti
Bernice Dressen
Sheila Driben
Jeanette Fuenning
Russell Head
Carol C. Holmes
Christopher David Illick
Jacqueline Elizabeth Jablon
James F. Jerome

William Eisner Lefkowitz
Ninfa Leo
Joan Mangam Wegner
Cecile Mitchell
Fred Myers
Richard Shafto Love Pearn
Naoma M. Schmidt
Anne Seabrook
Catherine Shook Smithwick
Joyce Smith
Anne Stoakes
Oscar S. Straus II
John Thompson

$1,000 to $4,999
Anonymous
ADAC
Mr. and Mrs. Paul S. Adler
Mr. Barry Akrongold
Mr. Louis Mendez and Mr. Charles Allem
Tina Alster, M.D.
Mr. and Mrs. Timothy John Alvino
Mr. and Mrs. Steven Ames
AMYLGEN
Mr. Richard Aner
Mr. and Mrs. John Angelo
Mr. and Mrs. Bonneau Ansley
Mr. and Mrs. Robert Aquilina
Mr. Peter Aresty
Ms. Marion Bachrach and Family
Mr. and Mrs. David M. Baldwin
Mr. and Mrs. Martin Balsam
Mr. and Mrs. David A. Bardes
Ms. Anne Barge Clegg
Mr. and Mrs. Ronald S. Baron
Ms. Mercedes T. Bass
Mr. and Mrs. Richard I. Beattie
Mr. and Dr. Stanley Bergman
Mr. and Mrs. Simon Beriro
Mr. Tony Bernhardt
Mr. Howard Bernick
The Honorable and Mrs. Stuart Bernstein
BioFocus
Mr. Steve Blacher
Mr. and Mrs. Dameron Black III
Mr. and Mrs. Robert S. Blank
Mr. and Mrs. Wolf Blitzer
Mr. and Mrs. Bernard Bloom
Ms. Faith Bobrow
Ms. Jeannine Bouillier Siegmond
Mr. and Mrs. Patrick Bousquet-Chavanne
Mr. and Mrs. Walter M. Bowen
Mr. and Mrs. Richard S. Braddock
Mr. and Mrs. Lawrence Brandt
Mr. and Mrs. John Brennan
Mr. and Mrs. Daniel J. Brigati
Mr. and Mrs. Peter R. Brinckerhoff
In Honor

In 2013, gifts were made to the ADDF in honor of the following individuals:

Sharrie M. Alechman
Claire E. Becker
Jean Brigati
Edna Constantine
Nancy Crown
Marti Dinerstein
Jean Ernst
Agnes Farrell
Betty Farrell
Mary Farrell
Phebe Farrow Port
William Ferguson
Barbara Fields
John Ford
Mel and Nancy Goodes
Anne Gottlieb
Grucci Family
Mrs. P.B. Harris
Pauline Harris
Leonard A. Lauder
Elise and Marc Lefkowitz

Emory University
Mrs. Deborah Epstein
Mrs. Nancy Epstein, Artistic Tile
Mr. and Mrs. Melvyn J. Estrin
Mr. and Mrs. Alfonso Fanjul
Ms. Samia Farouki
Mr. and Mrs. David C. Farrell
Ms. Phebe Farrow Port
Mr. and Mrs. Harry Fields
Ms. Debbie Forrest
Mr. and Mrs. Joe Foster
Mr. and Mrs. William Fowler
Mr. and Mrs. Sam Fox

Mr. and Mrs. Fabrizio Freda
Mr. Jay W. Freedman
Mr. and Mrs. Robert Fried
Ms. Charlotte Moss and Mr. Barry Friedberg
Ms. Carolee Friedlander
Ms. Anita Friedman
Mr. and Mrs. Ross S. Friedman
Mr. and Mrs. Ernie Fyrwald
Ms. Mary Galvin
Mr. David Gerson
Mr. Sam Ghusson
Mr. and Mrs. Robert Gibb

For more information about the ADDF, please visit www.AlzDiscovery.org
Neurotrack
New York Stem Cell Foundation, Inc.
Mr. and Mrs. William A. Nitze
Mr. and Mrs. McKee Nunnally
Mr. and Mrs. Andrew J. Nussbaum
Mr. and Mrs. Harold Ofstie
Ms. Victoria Palefsky
Mrs. Jean H. Pearman
Ms. Erica Peitler
Ms. Marsha Perreault
Ms. Connie Anne Phillips
Palindrome Design
Pillsbury Winthrop Shaw Pittman LLP
Ms. Veronique Gabai-Pinsky
Ms. Jackie Pletcher
Mr. and Mrs. Cedric Prouve
PsychoGenics, Inc.
QPS
reMYND
Renovo, Inc.
Mr. and Mrs. Mercer Reynolds
Mr. and Mrs. Lewis Rice
Mr. Stefan Richter
Ms. Mary Riddell
Mr. and Mrs. Maury H. Riff
Mr. and Mrs. Robert Ritter
Mr. and Mrs. Randy Rizor
Mrs. Sheila Johnson Robbins
The Robert F. and Eleonora W. McCabe Foundation
Mr. and Mrs. Mack Robinson
Friends of Sharon Rockefeller
Mr. and Mrs. John D. Rockefeller IV
Mr. and Mrs. Randolph K. Rolf
Dr. and Mrs. Leon Root
Mr. James Rose
Mr. and Mrs. Ronald Rosner
Ms. Janet C. Ross
Mr. and Mrs. Ralf Roth
Dr. and Mrs. Ronald M. Roth
Mr. and Mrs. Howard J. Rubenstein
Mr. Stephen I. Sadove
Ms. Sharon T. Sager and Mr. Loring Swasey

In Kind Gifts

Abrielle Fine Linens & Lingerie
Amaryllis Floral and Event Design
Antiques Market
Arkay Packaging
Aruna Seth
Atlanta Dream
Balance, Your Pilates, Yoga & GYROtonic Studio
Bedford Post Inn
Beverly Wilshire, A Four Seasons Hotel
BLT Steak
Blue Tulip Chocolates
Bobi Brown
Bumble and bumble.
Bunny Williams Inc.
Cafe Milano
Champion Beauty Supply
Chelsea Lately
Colliers International NY LLC
Nancy Corzine
DC Sedan and Limousine
Jay and Cindy DeFrancesco
Delta Air Lines
Dennis Dean A Catering Company
Design Cuisine
Di Modolo
Faith and Warren Diamond
Diener Jewelers, Allison Diener Perlmutter
The Estée Lauder Companies Inc.
Fabulous Things
Feld Entertainment
First Republic Bank
Four Seasons Resort Palm Beach
Andrew D. Gilbert
Glenmere Mansion
Gomez-Gracia
Gotham Dream Cars
Hermès
Oscar Heyman
Alex Hitz
The Hollywood Roosevelt Hotel
Honeybee
The Howard Gilman Foundation
Hu's Shoes & Hu's Wear
The Inn at Serenbe

For more information about the ADDF, please visit www.AlzDiscovery.org
Mr. and Mrs. Sal Salibello
SALON ILO
Ms. Kerri Scharlin and Mr. Peter Klosowicz
Peter M. Scheer DDS, M.S.
Mr. David Schiff
Ms. Jane Hartley and Mr. Ralph Schlosstein
Ms. Aileen Schruth
Mr. and Mrs. Edmondo Schwartz
Mr. and Mrs. William P. Scully
Mr. John Seabrook
Ms. Robyn Shepherd
The Shiloh Foundation
Mr. and Mrs. Charles Shoemate
The Carlynn and Lawrence Silverman Family Foundation Inc.
Mr. and Mrs. Albert Small, Jr.
Ms. Lesly Smith
Mr. and Mrs. Joseph E. Smith
Mr. and Mrs. Spencer Smul
Mr. and Mrs. Richard Solomon
Mr. Maurice Sonnenberg
Ms. Alicia Sontag
SRI International
Mr. and Mrs. James Star
Mr. and Mrs. Richard Stark
Mr. and Mrs. Ed Staros
Mr. and Mrs. Michael Steinhardt
Mr. and Mrs. Austin Stephens
Mrs. Joyce Sterling
Philip E. Stieg, M.D.
Dr. and Mrs. William K. Stubbs III
Mr. and Mrs. Mark Styslinger
Mr. and Mrs. Andrew Suzuki
Ms. Judy Swanson
T. Rowe Price Foundation, Inc.
Mr. and Mrs. Douglas T. Tansill
Mr. and Mrs. A. Alfred Taubman
Ms. Felicia Taylor
Mr. and Mrs. Joe Thomas
Lady Barbara Thomas Judge
Mr. and Mrs. Peter Thompson
Mr. and Mrs. William Tobin
Mrs. Julia Tolkan
Ms. Annie Totah
Ms. Lee Traub
Mr. W. J. Truettner, Jr.
Truist
Mr. John Tyers
UBS
Mr. and Mrs. James Ueltschi
United Way of New York City
Ms. Eunice C. Valdivia
The Honorable William J. Vanden Heuvel
Mr. and Mrs. Michael Voslow
Mr. and Mrs. Edwin A. Wahlen, Jr.
Ms. Ann Marie Huebner and Mr. Ross P. Waller
Ms. Cynthia Clift and Mr. David Wassong
Mr. and Mrs. Lorre R. Waxlax
Ms. Rosemary Fine Weaver
Ms. Jane Greenwald and Mr. Lawrence A. Wein
Mrs. John L. Weinberg
Mr. and Mrs. Jon Weiner
Dr. Arthur C. Weisenseel
Mr. and Mrs. Pat Welsh
Mr. Howard Wendy
Ms. Jennifer Wendy and Mr. Andrew Beckler
Mr. and Mrs. Mark West
Tina West, M.D.
Ms. Nan S. Whalen
Mr. and Mrs. Clifford Whitehall
Mrs. Malcolm Hewitt Wiener
Mr. and Mrs. Jeffrey Wilks
Ms. Jan Willinger
Mr. and Mrs. William Winslow
Ms. Helena Wong
Mr. and Mrs. Carl Zelinsky

$500 to $999
Mr. and Mrs. Mel Adler
Aon Foundation
Ms. Jan Aronson
Mr. Bill Assaad
Mr. and Mrs. William B. Astrop
Mr. and Mrs. John Bader
Brian Bai, M.D.

Steven Bailey, Ph.D.
Ms. Amy Bamford
Ms. Betty A. Barton
Mr. M. J. Bas
Ms. Marguerite C. Bateman
Mr. and Mrs. Charles H. Battle, Jr.
Ms. Linda Bedell
Ms. Gail Bendit
Mr. and Mrs. Douglas N. Benham
Mr. and Mrs. Bruce Berger
Mr. Jim Berge
Mr. and Mrs. Allan J. Berman
Mrs. Janet Black
Mr. George W. Booker
Theodoros Botsoglou, M.D.
The Boys & Girls Club of Bellport Area
Stefania Bradley, Ph.D.
Pamela Braker, M.D.
The Brooks Foundation
Ms. Virginia Brophy
Daniela Brunner, M.D.
Dr. Karen E. Burke and Mr. Peter J. Goulardis
Mr. Patrick Burkey
Mr. and Mrs. Matt Burrell
Ms. Mary K. Bush
Mr. Josh Cammer
Mr. and Mrs. John A. Canning
Ms. Iris Cantor
Mr. and Mrs. Gordon Caplan
Ms. Giosetta Capriati
Mr. Fred J. Carter, Jr.
Jianhua Chao, M.D.
Peter Cheung, Ph.D.
Chicago Estate Planning Council
Henry Chilton, M.D.
Mr. and Mrs. Neil Cohen
Ms. Beverly B. Coker
Ms. Karen Cook, MS
Mr. Jeremy Corkern
Ms. Ann Cousins
Cousins Properties Foundation Inc.
Mr. and Mrs. Ed Croft
Mr. and Mrs. Clifton Culberson
Ms. Corinne Davidov
Ms. Sandi A. Davidson
Mr. Philip Davis
Mr. and Mrs. Bruce Dayton
Mr. and Mrs. Arnaud de Borchgrave
Mr. David Dewees
Symeon Deres, M.D.
Mr. and Mrs. John Deushane
Mr. Zul Dhuuka
Ioannis Diakogiannis, M.D.
Mr. and Mrs. Samuel Difeo
Evangelia Dimitrakoudi, M.D.
Ms. Mary Wayne Dixon
Mr. and Mrs. J. Bennett Donaldson, Jr.
Mr. and Mrs. Marc Dorfman
Julie Douville, Ph.D.
The Duber Family Foundation, Inc.
Ms. Elizabeth M. Dugan
Ms. Donna Edbril
Mr. and Mrs. Robert G. Edge
Mr. and Mrs. Pat Epps
Mr. Stuart M. Fain
Mr. and Mrs. Thomas C. Farnsworth, Jr.
Mr. and Mrs. Kenneth Feld
Howard M. Fillit, M.D.
Mrs. Susan Forte
Mr. and Mrs. Michael E. Foster
Ms. Anita Kern and Mr. Carl Fowler
Mr. and Mrs. William H. Fox
Ms. Michelle L. Freeman
Mr. and Mrs. William Frick
Ms. Linda Fuselier and
Mr. Christopher Ogden
Mr. and Mrs. Todd Galkin
Gannett Foundation
Mr. and Mrs. Bruce Gendelman
Ms. Beata Glover
Evangelos Gogalis, M.D.
Michael Gold, M.D.
Ms. Edith Goldberg
Mr. Michael Golden
Ms. Ann Gottlieb
Mr. Michael B. Graff
Paschalia Grammena, MD
Mr. and Mrs. John W. Grant
Mr. Dean Gray
Mr. and Mrs. Hix Green
Mr. and Mrs. Ronald Greenberg
Mr. Alexis Gregory
Ms. Catherine Gropper
Ms. Betsy Grossman, Harry and
Beatrice Sley Foundation
Ms. Allison Grover
Ms. Louise S. Gunn
Ms. Lois Haber
Mr. John W. Hadden II
Mr. and Mrs. John Hall
Mr. and Mrs. Thomas H. Hall
Mr. E. Matthew Hare
Ms. Lisa Harwood and
Ms. Carolynn Silverman
Mrs. Bobba Paul Hauserman
Dr. Philip Haydon
Dr. Bibia Heidmann
Ms. Lesley Heller
Anonymous, in memory of
Mr. Jacques Boulanger
Mr. Ken C. Hicks
Mr. Adam Hinman
Ann and Bob Holder
Mr. and Mrs. Sherman Hotchkiss
Huff-Deuberry, Inc.
Mr. and Mrs. Edward Hutton
Ms. Susan Hyatt
Ms. Raeanne Hytome
Ms. Joan Jaco
Mr. and Mrs. Morton Janklow
Mr. and Mrs. R.B. Jennings, Jr.
Mr. and Mrs. Neil Johnson
Ms. Allison Johnson
Ms. Eugenia Jones
Ms. Judy Jordan
Judy & Howard Berkowitz Foundation
Mr. Fahad Kajani
Maria Karadakonti, M.D.
Mrs. Jayne Keith
Ms. Janet Kellett
Ms. Joan E. Kend
Mr. and Mrs. John R. Kennedy
Mr. and Mrs. William Kenyon
Mrs. Andre Kikoski
Ms. Phyllis L. Kim
Mr. and Mrs. Roger Kimmel
Paschalis Kirtsios, M.D.
Ms. Morley Klausner
Mr. W. Donald Knight
Dr. Samir Koirala
Honorable Thomas C. Korologos and
Honorable Ann McLaughlin Korologos
Ms. Elizabeth Szancer Kujawski and
Mr. Tom Zoufaly
Ms. Ann Kuscher
Mr. and Mrs. Richard Landau
Mr. Mel Laracey
Mr. and Mrs. Thomas P. Latimer
Ms. Susan Lee
Mr. John Lenhart
Ms. Marcia Levine
Mr. and Mrs. Jerrold G. Levy
Mr. Warren Lichtenstein
Mr. and Mrs. David Liebowitz
Ms. Susan Locke
Ms. Dena Lombardo
Ms. Sheila Lumsden
Mrs. Nancy Lynn
Ms. Erin M. Lyons
Mr. and Mrs. Barry MacTaggart
Ilias Manavis, M.D.
Mr. and Mrs. James L. Manley
Ms. Ellen Marks
Mr. and Mrs. James C. Marlas
Ms. Susan Masser
Mrs. Mary Ann Massey
Ms. Katherine Mayer
Mr. Lom McClan
Mr. and Mrs. Richard P. McCoy
Mr. Thompson McDaniel
Mr. and Mrs. Richard G. McDermott, Jr.
Mr. John McGuire
Please notify us if you have named the Alzheimer’s Drug Discovery Foundation in your will or trust. By doing so, you will become a member of our Legacy Society and be listed in the Annual Report, unless you prefer to remain anonymous.
Alzheimer’s Drug Discovery Foundation

**Statements of Financial Position**

<table>
<thead>
<tr>
<th>Assets</th>
<th>12/31/13</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and cash equivalents</td>
<td></td>
</tr>
<tr>
<td>Operating</td>
<td>$2,911,519</td>
</tr>
<tr>
<td>Restricted</td>
<td>27,900</td>
</tr>
<tr>
<td><strong>Total cash and cash equivalents</strong></td>
<td><strong>2,939,419</strong></td>
</tr>
<tr>
<td>Investment, at fair value</td>
<td>8,705,188</td>
</tr>
<tr>
<td>Contributions receivable</td>
<td>4,552,996</td>
</tr>
<tr>
<td>Due from Institute for the Study of Aging</td>
<td>68,815</td>
</tr>
<tr>
<td><strong>Other assets</strong></td>
<td>16,557</td>
</tr>
<tr>
<td><strong>Total assets</strong></td>
<td><strong>$16,282,975</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Liabilities and Net Assets</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Liabilities</td>
<td></td>
</tr>
<tr>
<td>Accounts payable and accrued liabilities</td>
<td>$51,249</td>
</tr>
<tr>
<td>Grants payable</td>
<td>8,665,995</td>
</tr>
<tr>
<td>Deferred revenue</td>
<td>30,765</td>
</tr>
<tr>
<td>Due to the Institute for the Study of Aging, Inc.</td>
<td>-</td>
</tr>
<tr>
<td><strong>Total liabilities</strong></td>
<td><strong>8,748,009</strong></td>
</tr>
<tr>
<td>Net assets</td>
<td></td>
</tr>
<tr>
<td>Unrestricted</td>
<td>6,491,418</td>
</tr>
<tr>
<td>Temporarily restricted</td>
<td>1,043,547</td>
</tr>
<tr>
<td><strong>Total net assets</strong></td>
<td><strong>7,534,965</strong></td>
</tr>
<tr>
<td><strong>Total liabilities and net assets</strong></td>
<td><strong>$16,282,974</strong></td>
</tr>
</tbody>
</table>

**Statement of Activities**

<table>
<thead>
<tr>
<th>Change In Net Assets</th>
<th>12/31/13</th>
</tr>
</thead>
<tbody>
<tr>
<td>Support and Revenues</td>
<td></td>
</tr>
<tr>
<td>Support</td>
<td></td>
</tr>
<tr>
<td>Contributions and grants</td>
<td>$7,150,947</td>
</tr>
<tr>
<td>In-kind contributions from the Institute for the Study of Aging, Inc.</td>
<td>3,212,178</td>
</tr>
<tr>
<td>Proceeds from special events, net of direct expenses</td>
<td>2,826,874</td>
</tr>
<tr>
<td>Revenues</td>
<td></td>
</tr>
<tr>
<td>Grant Returns</td>
<td>25,000</td>
</tr>
<tr>
<td>Conference registration fees and other income</td>
<td>249,603</td>
</tr>
<tr>
<td>Interest income</td>
<td>8,034</td>
</tr>
<tr>
<td><strong>Total support and revenues</strong></td>
<td><strong>13,472,636</strong></td>
</tr>
<tr>
<td>Expenses</td>
<td></td>
</tr>
<tr>
<td>Program services</td>
<td>9,870,696</td>
</tr>
<tr>
<td>Fund raising</td>
<td>1,341,435</td>
</tr>
<tr>
<td>Management and general</td>
<td>648,675</td>
</tr>
<tr>
<td><strong>Total expenses</strong></td>
<td><strong>11,860,806</strong></td>
</tr>
<tr>
<td><strong>Change In net assets</strong></td>
<td><strong>1,611,830</strong></td>
</tr>
<tr>
<td><strong>Net assets, beginning of year</strong></td>
<td><strong>5,923,136</strong></td>
</tr>
<tr>
<td><strong>Net assets, end of period</strong></td>
<td><strong>$7,534,966</strong></td>
</tr>
</tbody>
</table>

Audited financials available upon request

For more information about the ADDF, please visit [www.AlzDiscovery.org](http://www.AlzDiscovery.org)
ADDF 2013 Board of Governors and Overseers

Board of Governors

Honorary Chairman
Sandra Day O’Connor

Co-Chairmen
Leonard A. Lauder
Ronald S. Lauder

President
Nancy Corzine

Robert A. Belfer
Lady Lynn Forester de Rothschild
Bonnie Pfeifer Evans
Melvin R. Goodes
Nancy Goodes
Thomas F. McWilliams
Randal Sandler
Alice Shure
Peter J. Solomon
Sally Susman
Paula Zahn

Ex Officio
Howard Fillit, MD

Officers
Lisa Somar
Kevin Dieterich

Board of Overseers

Co-Chairmen
Sharon T. Sager
Randal Sandler

Carol Seabrook Boulanger
Charles Cangro
Faith Perlmutter Diamond
Julie Eskay-Eagle
Mitchell D. Eichen, JD, LLM
Allan Green, MD, PhD, JD
Christopher Johnson
Susan Roth Katzke
Elise Gelman Lefkowitz
Philip Lovett
Emilio Matt
Pamela J. Newman, PhD
Phebe Farrow Port
Joan Sutton Straus
Mary Rose Taylor
Alison Zaino
Linda S. Zambelli

As of December 31, 2013
ADDf Staff

Howard Fillit, MD
Founding Executive Director and Chief Science Officer

Diana Shineman, PhD
Director, Scientific Affairs

Rachel Lane, PhD
Assistant Director, Scientific Affairs

Penny Dacks, PhD
Assistant Director, Aging and Alzheimer's Prevention Program

Aaron Carman, PhD
Program Manager, Aging and Alzheimer's Disease Prevention

Sara Classen
Manager, Conferences and Meetings

Danielle Popow
Grants Assistant

Nancy Sanford
Vice President and Chief Philanthropy Officer

Mollie Wein
Assistant Director, Special Events

Dresden Joswig
Communications Manager

Elizabeth Feske
Database and Development Coordinator

Sarah Toepke
Development Associate

Joseph Trapani
Executive Assistant

Jessica Cavanaugh
Special Events Assistant

Rochelle Bloom
Communications and Marketing Consultant

Aspasia Moundros
Executive Assistant and Operations Coordinator

Katie Mischik
Office Manager

Ethan Hutchinson
Director, Finance and Administration

Diane Duong
Assistant Director, Finance and Administration

Finance

Administration
Since 1998, the Alzheimer’s Drug Discovery Foundation has granted more than $65 million to fund 450 Alzheimer’s drug discovery programs in 18 countries.